Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
Latest Information Update: 04 Dec 2024
Price :
$35 *
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Histiocytosis; Mantle-cell lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Rhabdoid tumour; Solid tumours; Synovial sarcoma
- Focus Adverse reactions
- Acronyms TRuST
- Sponsors Epizyme
- 27 Mar 2024 Planned End Date changed from 31 Dec 2024 to 3 Nov 2025.
- 27 Mar 2024 Planned primary completion date changed from 31 Dec 2024 to 3 Nov 2025.
- 24 Feb 2024 This trial has been completed in Belgium, According to Eudra record.